Randomized controlled trial of bushen yinao pill combined with conventional therapy on intestinal flora imbalance and cognitive function improvement in older patients with Alzheimer's disease.

IF 1.1 4区医学 Q4 PSYCHIATRY

International Journal of Psychiatry in Medicine Pub Date : 2024-12-12 DOI:10.1177/00912174241290962

Wei Wang, Ji Zhang, Cangda Li

{"title":"Randomized controlled trial of bushen yinao pill combined with conventional therapy on intestinal flora imbalance and cognitive function improvement in older patients with Alzheimer's disease.","authors":"Wei Wang, Ji Zhang, Cangda Li","doi":"10.1177/00912174241290962","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to evaluate the effects of the Bushen Yinao Pill, combined with standard therapy, on gut flora imbalances, inflammatory markers, and cognitive function in older patients with Alzheimer's disease (AD).Methods: A total of 136 AD patients treated at the Department of Neurology from August 2022 to September 2023 were randomly assigned to two groups: 68 patients received standard treatment (control group, CTG), and 68 patients received the Bushen Yinao Pill plus standard treatment (intervention group, ITG). Outcomes included TCM syndrome scores, gut microbiota composition, inflammatory markers, cognitive function, overall efficacy, and safety.Results: ITG showed significant reductions in syndrome scores as compared to CTG after treatment (P < 0.05). The ITG also showed significant increases in beneficial bacteria and decreases in harmful bacteria compared to the CTG (P < 0.05). Inflammatory markers (Aβ, IL-6, TNF-α) were reduced, and cognitive function improved more significantly in the ITG (P < 0.05). The effective rate was higher in the ITG, with no significant difference in adverse reactions between the groups (P > 0.05).Conclusion: The Bushen Yinao Pill, when combined with standard therapy, effectively regulates gut microbiota, reduces inflammatory markers, and enhances cognitive function in AD patients, showing a favorable safety profile. Further research is recommended to validate these findings in diverse populations.","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":" ","pages":"912174241290962"},"PeriodicalIF":1.1000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00912174241290962","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to evaluate the effects of the Bushen Yinao Pill, combined with standard therapy, on gut flora imbalances, inflammatory markers, and cognitive function in older patients with Alzheimer's disease (AD).

Methods: A total of 136 AD patients treated at the Department of Neurology from August 2022 to September 2023 were randomly assigned to two groups: 68 patients received standard treatment (control group, CTG), and 68 patients received the Bushen Yinao Pill plus standard treatment (intervention group, ITG). Outcomes included TCM syndrome scores, gut microbiota composition, inflammatory markers, cognitive function, overall efficacy, and safety.

Results: ITG showed significant reductions in syndrome scores as compared to CTG after treatment (P < 0.05). The ITG also showed significant increases in beneficial bacteria and decreases in harmful bacteria compared to the CTG (P < 0.05). Inflammatory markers (Aβ, IL-6, TNF-α) were reduced, and cognitive function improved more significantly in the ITG (P < 0.05). The effective rate was higher in the ITG, with no significant difference in adverse reactions between the groups (P > 0.05).

Conclusion: The Bushen Yinao Pill, when combined with standard therapy, effectively regulates gut microbiota, reduces inflammatory markers, and enhances cognitive function in AD patients, showing a favorable safety profile. Further research is recommended to validate these findings in diverse populations.

查看原文本刊更多论文

补肾脑丸联合常规治疗老年阿尔茨海默病患者肠道菌群失调及认知功能改善的随机对照研究。

目的：本研究旨在评价补肾益脑丸联合标准治疗对老年阿尔茨海默病（AD）患者肠道菌群失衡、炎症标志物和认知功能的影响。方法：选取2022年8月至2023年9月在神经内科治疗的136例AD患者，随机分为两组：68例患者接受标准治疗（对照组，CTG）， 68例患者接受补肾益脑丸加标准治疗（干预组，ITG）。结果包括中医证候评分、肠道菌群组成、炎症标志物、认知功能、总体疗效和安全性。结果：治疗后ITG组的证候评分较CTG组明显降低（P < 0.05）。与CTG相比，ITG有益菌数量显著增加，有害菌数量显著减少（P < 0.05）。炎症标志物（Aβ、IL-6、TNF-α）明显降低，认知功能明显改善（P < 0.05）。ITG组有效率较高，两组不良反应无显著差异（P < 0.05）。结论：补肾益脑丸联合标准治疗可有效调节AD患者肠道菌群，降低炎症标志物，增强认知功能，安全性较好。建议进一步研究以在不同人群中验证这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Psychiatry in Medicine 医学-精神病学

CiteScore

3.00

自引率

5.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The International Journal of Psychiatry in Medicine (IJPM) bridges the gap between clinical psychiatry research and primary care clinical research. Providing a forum for addressing: The relevance of psychobiological, psychological, social, familial, religious, and cultural factors in the development and treatment of illness; the relationship of biomarkers to psychiatric symptoms and syndromes in primary care...